Advertisement
Screener

ENVERIC BIOSCIENCES, INC. (ENVB) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

ENVERIC BIOSCIENCES, INC. Comprehensive Income

ENVERIC BIOSCIENCES, INC. (ENVB) reported Comprehensive Income of -$3.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14

  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$3.04M.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$1.64M.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$679.82K.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$3.39M.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$8.76M.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$9.60M.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$17.49M.
  • ENVERIC BIOSCIENCES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$19.31M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2026-06-30-$3.04M
10-Q · filed 2026-08-14
-$4.68M
10-Q · filed 2026-08-14
-$5.36M
derived: sum of 3 quarters · filed 2026-08-14
-$8.75M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$1.64M
10-Q · filed 2026-05-15
-$2.32M
derived: sum of 2 quarters · filed 2026-05-15
-$5.71M
derived: sum of 3 quarters · filed 2026-05-15
-$8.21M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$679.82K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27
-$4.07M
derived: sum of 2 quarters · filed 2026-03-27
-$6.57M
derived: sum of 3 quarters · filed 2026-08-14
-$8.76M
10-K · filed 2026-03-27
2025-09-30-$3.39M
10-Q · filed 2025-11-14
-$5.89M
derived: sum of 2 quarters · filed 2026-08-14
-$8.08M
10-Q · filed 2025-11-14
-$11.29M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$2.49M
10-Q · filed 2026-08-14
-$4.68M
10-Q · filed 2026-08-14
-$7.90M
derived: sum of 3 quarters · filed 2026-08-14
-$9.95M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$2.19M
10-Q · filed 2026-05-15
-$5.40M
derived: sum of 2 quarters · filed 2026-05-15
-$7.46M
derived: sum of 3 quarters · filed 2026-05-15
-$9.35M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$3.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27
-$5.27M
derived: sum of 2 quarters · filed 2026-03-27
-$7.16M
derived: sum of 3 quarters · filed 2026-03-27
-$9.60M
10-K · filed 2026-03-27
2024-09-30-$2.05M
10-Q · filed 2025-11-14
-$3.95M
derived: sum of 2 quarters · filed 2025-11-14
-$6.39M
10-Q · filed 2025-11-14
-$9.86M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$1.89M
10-Q · filed 2025-08-14
-$4.33M
10-Q · filed 2025-08-14
-$7.80M
derived: sum of 3 quarters · filed 2025-08-14
-$10.61M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$2.44M
10-Q · filed 2025-05-14
-$5.91M
derived: sum of 2 quarters · filed 2025-05-14
-$8.72M
derived: sum of 3 quarters · filed 2025-05-14
-$15.13M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31-$3.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
-$6.28M
derived: sum of 2 quarters · filed 2025-03-28
-$12.69M
derived: sum of 3 quarters · filed 2025-03-28
-$17.49M
10-K · filed 2025-03-28
2023-09-30-$2.81M
10-Q · filed 2024-11-14
-$9.22M
derived: sum of 2 quarters · filed 2024-11-14
-$14.02M
10-Q · filed 2024-11-14
-$22.72M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$6.41M
10-Q · filed 2024-08-12
-$11.21M
10-Q · filed 2024-08-12
-$19.91M
derived: sum of 3 quarters · filed 2024-08-12
-$22.93M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$4.80M
10-Q · filed 2024-05-15
-$13.50M
derived: sum of 2 quarters · filed 2024-05-15
-$16.52M
derived: sum of 3 quarters · filed 2024-05-15
-$19.67M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$8.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26
-$11.72M
derived: sum of 2 quarters · filed 2024-03-26
-$14.87M
derived: sum of 3 quarters · filed 2024-03-26
-$19.31M
10-K · filed 2024-03-26
2022-09-30-$3.02M
10-Q · filed 2023-11-13
-$6.17M
derived: sum of 2 quarters · filed 2023-11-13
-$10.61M
10-Q · filed 2023-11-13
-$52.56M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$3.15M
10-Q · filed 2023-08-11
-$7.59M
10-Q · filed 2023-08-11
-$49.54M
derived: sum of 3 quarters · filed 2023-08-11
-$52.26M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31-$4.44M
10-Q · filed 2023-05-15
-$46.39M
derived: sum of 2 quarters · filed 2023-06-09
-$49.11M
derived: sum of 3 quarters · filed 2023-06-09
-$50.05M
derived: sum of 4 quarters · filed 2023-06-09
2021-12-31-$41.95M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-09
-$44.67M
derived: sum of 2 quarters · filed 2023-06-09
-$45.61M
derived: sum of 3 quarters · filed 2023-06-09
-$48.83M
10-K/A · filed 2023-06-09
2021-09-30-$2.72M
10-Q · filed 2022-11-14
-$3.66M
derived: sum of 2 quarters · filed 2022-11-14
-$6.88M
10-Q · filed 2022-11-14
-$11.40M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$941.55K
10-Q · filed 2022-08-12
-$4.16M
10-Q · filed 2022-08-12
-$8.68M
derived: sum of 3 quarters · filed 2022-08-12
-$9.25M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$3.21M
10-Q · filed 2022-05-13
-$7.74M
derived: sum of 2 quarters · filed 2022-05-13
-$8.31M
derived: sum of 3 quarters · filed 2022-05-13
-$9.14M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$4.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
-$5.09M
derived: sum of 2 quarters · filed 2022-03-31
-$5.92M
derived: sum of 3 quarters · filed 2022-03-31
-$7.03M
10-K · filed 2022-03-31
2020-09-30-$572.64K
10-Q · filed 2021-11-15
-$1.40M
derived: sum of 2 quarters · filed 2021-11-15
-$2.51M
10-Q · filed 2021-11-15
-$5.98M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30-$828.46K
10-Q · filed 2021-08-13
-$1.94M
10-Q · filed 2021-08-13
-$5.41M
derived: sum of 3 quarters · filed 2021-08-13
-$5.49M
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31-$1.93M
10-Q · filed 2020-05-15
-$4.58M
derived: sum of 2 quarters · filed 2020-11-16
-$4.66M
derived: sum of 3 quarters · filed 2020-11-16
-$6.04M
derived: sum of 4 quarters · filed 2020-11-16
2019-12-31-$2.65M
derived: 10-Q 12 month − 10-Q 9 month · filed 2020-11-16
-$2.73M
derived: sum of 2 quarters · filed 2020-11-16
-$4.11M
derived: sum of 3 quarters · filed 2020-11-16
-$6.06M
10-Q · filed 2020-11-16
-$6.06M
10-K · filed 2020-03-25
2019-09-30-$83.44K
10-Q · filed 2019-11-08
-$1.46M
derived: sum of 2 quarters · filed 2019-11-08
-$3.41M
10-Q · filed 2019-11-08
-$23.23M
derived: sum of 4 quarters · filed 2020-08-12
2019-06-30-$1.38M
10-Q · filed 2019-08-14
-$3.33M
10-Q · filed 2019-08-14
-$23.15M
derived: sum of 3 quarters · filed 2020-08-12
-$19.26M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31-$1.95M
10-Q · filed 2020-05-15
-$21.77M
derived: sum of 2 quarters · filed 2020-08-12
-$17.88M
derived: sum of 3 quarters · filed 2020-08-12
-$19.28M
derived: sum of 4 quarters · filed 2020-08-12
2018-12-31-$19.82M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-12
-$15.93M
derived: sum of 2 quarters · filed 2020-08-12
-$17.33M
derived: sum of 3 quarters · filed 2020-08-12
-$19.43M
10-K/A · filed 2020-08-12
2018-09-30$3.88M
10-Q · filed 2019-11-08
$2.49M
derived: sum of 2 quarters · filed 2019-11-08
$388.69K
10-Q · filed 2019-11-08
-$1.10M
derived: sum of 4 quarters · filed 2019-11-08
2018-06-30-$1.40M
10-Q · filed 2019-08-14
-$3.50M
10-Q · filed 2019-08-14
-$4.99M
derived: sum of 3 quarters · filed 2019-08-14
-$9.61M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31-$2.10M
10-Q · filed 2019-05-14
-$3.59M
derived: sum of 2 quarters · filed 2019-05-14
-$8.22M
derived: sum of 3 quarters · filed 2019-05-14
-$12.00M
derived: sum of 4 quarters · filed 2019-05-14
2017-12-31-$1.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26
-$6.12M
derived: sum of 2 quarters · filed 2019-03-26
-$9.90M
derived: sum of 3 quarters · filed 2019-03-26
-$11.12M
10-K · filed 2019-03-26
2017-09-30-$4.62M
10-Q · filed 2018-11-14
-$8.41M
derived: sum of 2 quarters · filed 2018-11-14
-$9.63M
10-Q · filed 2018-11-14
-$8.33M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30-$3.79M
10-Q · filed 2018-08-14
-$5.00M
10-Q · filed 2018-08-14
-$3.70M
derived: sum of 3 quarters · filed 2018-08-14
-$5.42M
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31-$1.22M
10-Q · filed 2018-05-15
$83.89K
derived: sum of 2 quarters · filed 2018-05-15
-$1.63M
derived: sum of 3 quarters · filed 2018-05-15
-$2.85M
derived: sum of 4 quarters · filed 2018-05-15
2016-12-31$1.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02
-$418.04K
derived: sum of 2 quarters · filed 2018-04-02
-$1.63M
derived: sum of 3 quarters · filed 2018-04-02
-$2.79M
10-K · filed 2018-04-02
2016-09-30-$1.72M
10-Q · filed 2017-11-13
-$2.93M
derived: sum of 2 quarters · filed 2017-11-13
-$4.09M
10-Q · filed 2017-11-13
2016-06-30-$1.21M
10-Q · filed 2017-08-14
-$2.37M
10-Q · filed 2017-08-14
2015-12-31-$814.08K
10-K/A · filed 2017-04-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
Pulmatrix, Inc. (PULM)United States$0.006B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
EXICURE, INC. (XCUR)United States$0.008B-1.54